![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 3 of 3. This is the beginning of the thread.
Posted by ed_uk on February 25, 2006, at 17:22:25
'Seizure and abnormal heart rhythm warning on atomoxetine
Warnings on the risk of seizures and abnormal heart rhythm when taking atomoxetine (Strattera) have been set out in a Medicines and Healthcare products Regulatory Agency letter to doctors.
The letter follows a Europe-wide review of the risks and benefits of atomoxetine. The new advice to prescribers is that seizures are a potential risk with atomoxetine, that treatment should, therefore, be introduced with caution in patients with a history of seizure and that discontinuation should be considered in patients who develop seizures or who experience more frequent seizures. The letter also states that QT interval prolongation has been associated with atomoxetine treatment and that atomoxetine should, therefore, be used with caution in those with congenital or acquired long QT or a family history of QT prolongation. Strattera’s summary of product characteristics is being updated to reflect these new warnings, the MHRA says.
The MHRA is also reminding prescribers that patients should be monitored for signs of depression, suicidal thoughts or suicidal behaviour and referred for appropriate treatment if necessary and that atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury and should not be restarted.'
Posted by alohashirt on February 25, 2006, at 21:54:34
In reply to Strattera: new warnings in the UK, posted by ed_uk on February 25, 2006, at 17:22:25
I felt a surge of happiness when I stopped Stratterra. In hindsight I had been feeling bleak for almost a year. I have felt much, much happier w/o Strattera. What is scary is that I thought I had insight yet I didn't see this happening at the time.> 'Seizure and abnormal heart rhythm warning on atomoxetine
>
> Warnings on the risk of seizures and abnormal heart rhythm when taking atomoxetine (Strattera) have been set out in a Medicines and Healthcare products Regulatory Agency letter to doctors.
>
> The letter follows a Europe-wide review of the risks and benefits of atomoxetine. The new advice to prescribers is that seizures are a potential risk with atomoxetine, that treatment should, therefore, be introduced with caution in patients with a history of seizure and that discontinuation should be considered in patients who develop seizures or who experience more frequent seizures. The letter also states that QT interval prolongation has been associated with atomoxetine treatment and that atomoxetine should, therefore, be used with caution in those with congenital or acquired long QT or a family history of QT prolongation. Strattera’s summary of product characteristics is being updated to reflect these new warnings, the MHRA says.
>
> The MHRA is also reminding prescribers that patients should be monitored for signs of depression, suicidal thoughts or suicidal behaviour and referred for appropriate treatment if necessary and that atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury and should not be restarted.'
>
Posted by ed_uk on February 26, 2006, at 11:11:05
In reply to Re: Strattera: new warnings in the UK, posted by alohashirt on February 25, 2006, at 21:54:34
Hi
The suicide warning was one of the first warnings we got with Strattera in the UK!
Ed
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.